| Active substance | daunorubicin and cytarabine |
| Holder | Bionical Limited T/A Bionical Emas |
| Status | closed |
| Indication | Newly diagnosed, treatment-related acute myeloid Leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 24/11/2022 |